MR spectroscopy and diffusion imaging in people with human immunodeficiency virus: Relationships to clinical and immunologic findings.
DWI
HIV
MRS
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
20
08
2021
received:
04
08
2021
accepted:
25
08
2021
pubmed:
15
9
2021
medline:
22
3
2022
entrez:
14
9
2021
Statut:
ppublish
Résumé
People with human immunodeficiency virus (HIV; PWH) present a complex array of immunologic and medical disorders that impact brain structure and metabolism, complicating the interpretation of neuroimaging. This pilot study of well-characterized multi-morbid PWH examined how medical and immunologic factors predicted brain characteristics on proton MR spectroscopy (1H-MRS) and diffusion-weighted imaging (DWI). Eighteen individuals on combination antiretroviral therapy (cART), with mean age of 56 years, underwent medical history review, neuroimaging, and on the day of imaging, blood draw for assay of 20 plasma cytokines and flow cytometric characterization of peripheral blood mononuclear cell subsets. Predictors of n-acetyl aspartate, choline, myoinositol, glutamate/glutamine, fractional anisotropy and mean diffusivity were identified through bivariate correlation; those significant at p < .1000 were advanced to multivariate analysis, with models created for each neuroimaging outcome. Monocyte subsets and diverse cytokines accounted for 16 of 25 (64%) variables predicting 1H-MRS spectra in frontal gray and white matter and basal ganglia; monocyte subsets did not predict any DWI characteristic. In contrast, age, presence of hypertension, and duration of HIV infection accounted for 13 of 25 (52%) variables predicting diffusion characteristics in the corpus callosum, thalamic radiations, and basal ganglia but only 3 of 25 (12%) predictors of 1H-MRS features. 1H-MRS neurometabolites were most often predicted by immunologic factors sensitive to temporal variation, whereas DWI metrics were more often related to longer-term disease state. In multi-morbid cART-era populations, selection and interpretation of neuroimaging modalities should account for complex temporal and pathogenetic influences of immunologic abnormality, disease state, and aging.
Sections du résumé
BACKGROUND AND PURPOSE
People with human immunodeficiency virus (HIV; PWH) present a complex array of immunologic and medical disorders that impact brain structure and metabolism, complicating the interpretation of neuroimaging. This pilot study of well-characterized multi-morbid PWH examined how medical and immunologic factors predicted brain characteristics on proton MR spectroscopy (1H-MRS) and diffusion-weighted imaging (DWI).
METHODS
Eighteen individuals on combination antiretroviral therapy (cART), with mean age of 56 years, underwent medical history review, neuroimaging, and on the day of imaging, blood draw for assay of 20 plasma cytokines and flow cytometric characterization of peripheral blood mononuclear cell subsets. Predictors of n-acetyl aspartate, choline, myoinositol, glutamate/glutamine, fractional anisotropy and mean diffusivity were identified through bivariate correlation; those significant at p < .1000 were advanced to multivariate analysis, with models created for each neuroimaging outcome.
RESULTS
Monocyte subsets and diverse cytokines accounted for 16 of 25 (64%) variables predicting 1H-MRS spectra in frontal gray and white matter and basal ganglia; monocyte subsets did not predict any DWI characteristic. In contrast, age, presence of hypertension, and duration of HIV infection accounted for 13 of 25 (52%) variables predicting diffusion characteristics in the corpus callosum, thalamic radiations, and basal ganglia but only 3 of 25 (12%) predictors of 1H-MRS features.
CONCLUSIONS
1H-MRS neurometabolites were most often predicted by immunologic factors sensitive to temporal variation, whereas DWI metrics were more often related to longer-term disease state. In multi-morbid cART-era populations, selection and interpretation of neuroimaging modalities should account for complex temporal and pathogenetic influences of immunologic abnormality, disease state, and aging.
Identifiants
pubmed: 34520593
doi: 10.1111/jon.12931
pmc: PMC8752497
mid: NIHMS1736584
doi:
Substances chimiques
Aspartic Acid
30KYC7MIAI
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
158-170Subventions
Organisme : NIMH NIH HHS
ID : R01 MH112391
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS108801
Pays : United States
Organisme : NIMH NIH HHS
ID : U24 MH100931
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001433
Pays : United States
Informations de copyright
© 2021 American Society of Neuroimaging.
Références
AIDS. 2019 Jun 1;33(7):1175-1185
pubmed: 30870195
Mol Psychiatry. 2007 Jul;12(7):611, 691-702
pubmed: 17245325
J Magn Reson Imaging. 2003 Jun;17(6):625-33
pubmed: 12766890
PLoS One. 2013 Jul 31;8(7):e70164
pubmed: 23936155
AIDS. 2016 Jan;30(2):311-22
pubmed: 26691551
J Hepatol. 2013 Oct;59(4):651-7
pubmed: 23680314
PLoS One. 2012;7(4):e33809
pubmed: 22496768
J Neurovirol. 2011 Feb;17(1):63-9
pubmed: 21246320
AJNR Am J Neuroradiol. 2005 Mar;26(3):585-90
pubmed: 15760870
Magn Reson Med. 2008 Mar;59(3):528-34
pubmed: 18224697
Neuroimage. 2004 Nov;23(3):928-35
pubmed: 15528093
J Neurovirol. 2016 Apr;22(2):201-12
pubmed: 26446690
J Infect Dis. 2009 Oct 15;200(8):1212-5
pubmed: 19728788
J Neurovirol. 2015 Oct;21(5):559-67
pubmed: 26069183
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
Exp Mol Med. 2021 Feb;53(2):168-188
pubmed: 33568752
J Neuroimmune Pharmacol. 2019 Mar;14(1):120-133
pubmed: 29981000
Drug Alcohol Depend. 2019 Apr 1;197:288-298
pubmed: 30875650
J Clin Exp Neuropsychol. 2004 Sep;26(6):759-78
pubmed: 15370374
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):423-430
pubmed: 28796748
AIDS. 2020 Mar 1;34(3):415-426
pubmed: 31725432
J Neurovirol. 2011 Oct;17(5):477-86
pubmed: 21965122
PLoS One. 2014 Jan 06;9(1):e84822
pubmed: 24400118
J Neurovirol. 2016 Jun;22(3):389-99
pubmed: 26689572
NMR Biomed. 2001 Jun;14(4):260-4
pubmed: 11410943
Biosci Rep. 2018 Sep 7;38(5):
pubmed: 30104398
Cytometry A. 2018 May;93(5):548-555
pubmed: 29624852
Neuroradiology. 2012 Feb;54(2):113-21
pubmed: 21424708
J Neuroimaging. 2018 May;28(3):320-327
pubmed: 29380545
J Neurovirol. 2013 Jun;19(3):209-18
pubmed: 23613008
J Neurovirol. 2014 Jun;20(3):294-303
pubmed: 24696364
Neuroimage Clin. 2019;24:101945
pubmed: 31374399
Neurology. 2016 Apr 12;86(15):1425-1432
pubmed: 26911637
J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35
pubmed: 25622053
PLoS One. 2013 Jul 26;8(7):e69270
pubmed: 23922698
Neurology. 2006 Apr 25;66(8):1255-7
pubmed: 16636247
JCI Insight. 2021 Jun 8;6(11):
pubmed: 33914710
Virol J. 2012 Aug 27;9:174
pubmed: 22925532
J Neurol. 2016 Jun;263(6):1146-55
pubmed: 27094571
J Neurovirol. 2012 Aug;18(4):303-12
pubmed: 22585287
J Neuroimmunol. 2016 Dec 15;301:41-48
pubmed: 27836178
Proteomics Clin Appl. 2010 Mar;4(3):295-303
pubmed: 21137050
Semin Neurol. 2014 Feb;34(1):89-102
pubmed: 24715492
Pharmacol Biochem Behav. 2021 Jan;200:173090
pubmed: 33333132